Zepbound Side Effects: Full Breakdown by Frequency

Nausea, diarrhea, constipation and vomiting are among the most common Zepbound side effects. Many digestive events occur during dose increases and decrease over time, but severe or persistent symptoms need assessment. A symptom being common does not make every episode harmless.¹¹

Use the warning signs first, then the tables to compare symptoms and trial frequencies. These are population results, not a prediction of what you will experience or a personal treatment plan.

Warning signs that need prompt help

These warnings come from the prescribing information and patient-counseling instructions. They are separate from the routine adverse-reaction percentages below. Suspected pancreatitis and serious hypersensitivity require stopping Zepbound and prompt medical assessment under the label; do not wait for a routine follow-up.¹¹¹

Common symptoms: the pattern and when to contact care

The label reports that most nausea, vomiting and diarrhea events occurred during dose escalation and decreased over time. It does not establish one recovery deadline for every person or every symptom. Reviews across the tirzepatide trial program also found predominantly mild-to-moderate gastrointestinal events, with tolerability an important reason for stopping treatment.⁷⁸¹¹

Describe what changed, when it started, your last injection and any recent dose increase. Include whether you can eat and drink normally and whether symptoms interfere with daily activities. A new symptom should not automatically be blamed on the injection—or dismissed because it is not in a common-effects table.

For more detail, see nausea and vomiting, diarrhea, constipation, injection-site reactions and fatigue.

How often each reaction occurred, by dose

The following table reproduces the percentages in the current label’s Table 1. It pools two placebo-controlled weight-reduction trials in adults with obesity or overweight, with or without type 2 diabetes. Group sizes were 958 on placebo, 630 on 5 mg, 948 on 10 mg and 941 on 15 mg. These are maintenance-dose trial groups, not results for the 2.5 mg starting dose.¹¹

A higher dose does not mean a higher percentage in every row. For example, nausea was reported in 29% at 10 mg and 28% at 15 mg, while constipation was reported in 17%, 14% and 11% across the three doses. Do not treat the table as a personal dose-selection tool.¹¹

The label groups some related terms together: abdominal pain includes abdominal discomfort and tenderness; injection-site reactions include redness, bruising, itching and pain; fatigue includes weakness, lethargy and malaise. Trial percentages are not severity scores, and the table does not include every possible adverse reaction.¹¹

Serious precautions are a separate comparison

The frequency table cannot tell you whether a new symptom is safe to watch at home. Some important warnings are based on animal findings, postmarketing reports or specific patient circumstances rather than a common-event percentage.

The thyroid warning concerns C-cell tumors in rats; whether Zepbound causes these tumors in humans is unknown. A personal or family history of medullary thyroid carcinoma, or MEN 2, is a contraindication. A previous serious hypersensitivity reaction to tirzepatide or an ingredient is also a contraindication. These are not arbitrary “high-risk” scores.¹¹¹

For gallbladder context, the label reports cholecystitis in 0.7% on Zepbound versus 0.2% on placebo. A class-wide meta-analysis found increased gallbladder and biliary disease risk. A tirzepatide-specific pancreatitis/biliary review offers additional trial context, but a study finding that does not show a statistically significant pancreatitis increase does not remove the label’s warning or the need to assess concerning pain.⁹¹⁰¹¹

Read the dedicated guides on pancreatitis, gallbladder problems, gastroparesis and ileus, low blood sugar and thyroid warnings.

Before starting or changing the dose

Zepbound starts at 2.5 mg weekly for four weeks. The 2.5 mg dose is for initiation, not maintenance. The label uses 2.5 mg increases after at least four weeks at the current dose and asks clinicians to consider response and tolerability. The maximum is 15 mg weekly. Maintenance choices differ between weight management and obstructive sleep apnea.¹¹

Do not accelerate the schedule or add an injection to compensate for limited appetite effects. If digestive symptoms are severe, persistent or limiting fluid intake, report them before following another planned increase. For the actual schedule, use the dosage chart; for an interruption, see restarting after a break. A missed-dose rule is not a plan for restarting at a high dose after a long gap.

Tell the procedure team if surgery, anesthesia or deep sedation is planned. The label reports aspiration and says data are insufficient to determine whether temporarily stopping Zepbound or changing fasting instructions reduces the risk. Follow individualized instructions rather than a universal hold interval from an online guide.¹¹ See tirzepatide before surgery.

Other changes people ask about

Hair loss was reported in the trials and was associated with weight reduction in the label. That does not prove one mechanism for every person’s shedding or establish a guaranteed regrowth date. See the hair-loss guide if it is persistent or concerning.¹¹

Changes in breast volume, body shape and foot symptoms are different questions from the common-reaction table. Their absence from that table is not proof that a new symptom requires no assessment. Dry mouth or dry throat occurred in 1% versus 0.1% on placebo, and altered taste in 0.4% versus none on placebo. These are separately reported below the common-reaction table’s inclusion threshold; our teeth and dry-mouth guide explains the distinctions.¹¹

For new visual symptoms, contact the treating clinician; sudden or significant vision changes need prompt assessment. Our vision and NAION guide separates the developing evidence from the labeled diabetic-retinopathy precaution.

Weigh tolerability alongside the reason for treatment

SURMOUNT-1 and SURMOUNT-2 established weight-reduction benefits in different adult populations, while SURMOUNT-5 directly compared tirzepatide with semaglutide. SURMOUNT-OSA studied adults with obesity and moderate-to-severe obstructive sleep apnea. These benefits matter, but they do not justify ignoring severe symptoms.²³⁵⁶

SURMOUNT-4 showed substantial regain after treatment withdrawal compared with continued treatment. If tolerability is making you consider stopping, discuss a plan with the prescriber rather than assuming the only choices are enduring symptoms or changing treatment without support.⁴

The evidence guide, tirzepatide-versus-semaglutide comparison and patient-experience review provide the broader context. Include alcohol use, antidepressants, other medicines and your medical history in that discussion. If comparing access options, our provider comparison explains the care and cost questions to ask.